Semax is a synthetic heptapeptide with a growing body of research examining its neurotrophic properties. Here's what the current scientific literature reveals about this ACTH-derived neuropeptide.
Part of the PeptidesATX Research Hub
Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-10. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The peptide was originally developed in the late 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, where researchers were investigating the non-hormonal properties of ACTH fragments.
What makes Semax particularly interesting from a research perspective is its relationship to ACTH. While full-length ACTH (39 amino acids) primarily functions as a hormone that stimulates the adrenal cortex to produce cortisol, the shorter ACTH(4-10) fragment lacks this hormonal activity entirely. Instead, this fragment retains and, in the case of Semax's modified form, enhances a separate set of properties related to neurotrophic signaling and neuroprotection.
The modification from native ACTH(4-7) to Semax involved adding a Pro-Gly-Pro tripeptide to the C-terminus, which significantly increases the peptide's resistance to enzymatic degradation. This structural modification extends the peptide's biological half-life while preserving its neurotrophic signaling properties, making it far more practical as a research tool than the native ACTH fragment.
In the research literature, Semax has been the subject of hundreds of peer-reviewed publications examining its effects on neurotrophic factor expression, neuronal survival, and neuroprotective mechanisms. It has been studied extensively in Russian research institutions and has gained increasing attention from international research groups investigating neuropeptide signaling pathways.
The primary area of Semax research centers on its interaction with neurotrophic signaling pathways — the molecular networks that regulate neuronal growth, survival, differentiation, and synaptic plasticity.
Brain-Derived Neurotrophic Factor (BDNF) is one of the most extensively studied neurotrophins in modern neuroscience. It plays critical roles in neuronal survival, synaptic plasticity, learning and memory consolidation, and neurogenesis. BDNF signals primarily through the TrkB (tropomyosin receptor kinase B) receptor, activating downstream cascades including the MAPK/ERK, PI3K/Akt, and PLCγ pathways.
Multiple research groups have demonstrated that Semax can upregulate BDNF expression in various experimental models. Studies in rodent brain tissue have shown increased BDNF mRNA and protein levels following Semax administration, with effects observed in the hippocampus, cortex, and basal forebrain — regions critical for cognitive function and memory formation.
The mechanism through which Semax upregulates BDNF is an active area of investigation. Current evidence suggests that Semax may influence BDNF expression through multiple pathways, including modulation of melanocortin receptors (MC3R and MC4R), which are expressed throughout the central nervous system and have been linked to neurotrophic factor regulation.
Beyond BDNF, research has examined Semax's effects on other neurotrophins. Studies have reported that Semax can influence the expression of Nerve Growth Factor (NGF) and its receptor system. NGF is essential for the survival and maintenance of specific neuronal populations, particularly cholinergic neurons of the basal forebrain.
The ability of Semax to modulate multiple neurotrophins simultaneously distinguishes it from compounds that target a single growth factor pathway. This multi-neurotrophin influence makes Semax a valuable research tool for studying the coordinated regulation of neurotrophic factor networks.
Several research groups have investigated the neuroprotective properties of Semax in models of neuronal stress and injury. Studies have examined Semax in the context of oxidative stress, excitotoxicity, and ischemic conditions using both in vitro neuronal cultures and in vivo animal models.
In oxidative stress models, Semax has been reported to enhance antioxidant enzyme expression and reduce markers of oxidative damage in neuronal tissue. In excitotoxicity models, where excessive glutamate receptor activation leads to neuronal death, Semax administration has been associated with improved neuronal survival rates. These neuroprotective effects are thought to be mediated, at least in part, through the BDNF-TrkB signaling axis and downstream anti-apoptotic pathways.
The sustained research interest in Semax reflects several properties that make it a particularly useful tool for neuroscience research.
Selective neurotrophic activity. Unlike full-length ACTH, which has significant hormonal effects on adrenal function, Semax lacks adrenocorticotropic activity. This selectivity allows researchers to study neurotrophic and neuroprotective mechanisms without the confounding variable of adrenal stimulation. The separation of neurotrophic from hormonal activity makes Semax a cleaner research tool than the parent hormone.
Multi-pathway engagement. Semax influences multiple neurotrophic pathways simultaneously, including BDNF, NGF, and associated receptor systems. This multi-target profile makes it useful for studying how different neurotrophic pathways interact and coordinate neuronal function — a central question in modern neuroscience.
Enzymatic stability. The Pro-Gly-Pro modification gives Semax significantly greater stability than native ACTH fragments, which are rapidly degraded by peptidases. This enhanced stability makes Semax practical for experiments that require sustained peptide exposure over hours or days, expanding the range of experimental designs that can incorporate it.
Extensive literature base. With hundreds of published studies spanning several decades, Semax benefits from a substantial body of existing research data. New studies can build on established dose-response relationships, time-course data, and mechanistic frameworks, accelerating the pace of discovery.
Melanocortin receptor research. Semax's interaction with melanocortin receptors (particularly MC3R and MC4R) positions it within the broader field of melanocortin system research. The melanocortin system is involved in a wide range of biological processes including energy homeostasis, inflammation, and neuroprotection, making Semax relevant to research programs studying any of these areas.
Semax is employed in various laboratory and experimental research contexts, each leveraging different aspects of its neurotrophic and signaling properties.
Cell culture studies using primary neurons, neuronal cell lines, or stem cell-derived neurons represent one of the primary applications of Semax in research. These models allow precise control of peptide concentration and exposure duration, and enable detailed molecular analysis of signaling pathway activation. Researchers use Semax in these systems to study neurotrophic factor expression dynamics, neuroprotective signaling cascades, and neuronal differentiation processes.
In vivo research with Semax has been conducted in various preclinical models examining neurotrophic signaling under both normal and stress conditions. Animal studies have provided important data on bioavailability, tissue distribution, dose-response relationships, and the systemic effects of Semax administration. These studies inform the design of more targeted in vitro experiments and contribute to understanding how neurotrophic peptide signaling operates within intact biological systems.
Genomic and transcriptomic analyses have revealed that Semax administration affects the expression of hundreds of genes in neuronal tissue. Microarray and RNA-sequencing studies have identified changes in gene expression patterns related to neurotrophic signaling, synaptic plasticity, immune modulation, and vascular function. These broad-spectrum transcriptomic effects highlight the complexity of Semax's biological activity and continue to generate new research hypotheses.
As a modified ACTH fragment, Semax serves as a research tool for studying the melanocortin receptor system in the central nervous system. Its interactions with MC3R and MC4R provide insight into how melanocortin signaling regulates neurotrophic factor expression and neuroprotective responses — an area of growing interest in neuropharmacology research.
The quality of research peptides directly impacts the reliability and reproducibility of experimental results. When sourcing Semax for laboratory research, several factors should guide supplier selection.
Research-grade Semax should be verified by third-party analytical testing. At minimum, this includes HPLC analysis confirming ≥98% purity and mass spectrometry (MS) confirming the correct molecular weight and amino acid sequence. These results should be documented in a batch-specific Certificate of Analysis (COA) that corresponds to the exact lot being purchased.
Proper lyophilization is essential for peptide stability. The lyophilized product should be a white to off-white powder, free of visible impurities. Suppliers should maintain appropriate cold-chain storage and shipping conditions to prevent degradation during transit. Once received, lyophilized Semax should be stored at -20°C or below.
Legitimate research peptide suppliers label all products clearly as "for research use only" and do not make therapeutic, medical, or health-related claims. Suppliers that market peptides with implied clinical benefits should be avoided, as this indicates non-compliance with regulatory standards and may correlate with lower quality control practices.
Reputable suppliers provide accessible COAs, respond to questions about their analytical methods, and maintain consistent product quality across batches. Look for suppliers that make their testing documentation readily available rather than requiring extensive follow-up to obtain basic quality data.
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been extensively studied for its neurotrophic and neuroprotective properties in laboratory research settings.
Research has demonstrated that Semax can upregulate the expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB in various experimental models. BDNF is one of the most important neurotrophins involved in neuronal survival, synaptic plasticity, and neurogenesis, making the Semax-BDNF relationship a key focus of neuropeptide research.
Semax is used in laboratory research to study neurotrophic signaling pathways, BDNF expression, neuronal survival mechanisms, and neuroprotective responses. It is administered in controlled experimental settings including cell culture models, in vitro neuronal assays, and preclinical animal studies.
Key factors include third-party HPLC purity testing (≥98%), batch-specific Certificates of Analysis with mass spectrometry confirmation, proper lyophilization, research-use-only labeling, and cold-chain shipping when required. Avoid suppliers that make therapeutic or medical claims about Semax.
PeptidesATX offers Semax 10mg with third-party purity testing, batch-specific COA, and same-day shipping from Austin, TX.
View Semax 10mg Browse All PeptidesDisclaimer: This compound is intended for laboratory research use only. It is not approved for human or veterinary use.